IMMUNITYBIO, INC. Additional Paid in Capital, Common Stock
IMMUNITYBIO, INC. (IBRX) had Additional Paid in Capital, Common Stock of $3.52 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-04
- 2026-06-30: Additional Paid in Capital, Common Stock $3.52B.
- 2026-03-31: Additional Paid in Capital, Common Stock $3.46B.
- 2025-12-31: Additional Paid in Capital, Common Stock $3.20B.
- 2025-09-30: Additional Paid in Capital, Common Stock $3.14B.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $3.52B 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $3.46B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $3.20B 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $3.14B 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $3.01B 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $2.89B 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $2.88B 10-K · filed 2026-02-23 | |
| 2024-09-30 | $2.57B 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $2.53B 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $2.40B 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $2.37B 10-K · filed 2025-03-03 | |
| 2023-09-30 | $2.32B 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $1.99B 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $1.97B 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $1.93B 10-K · filed 2024-03-19 | |
| 2022-09-30 | $1.84B 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $1.74B 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $1.73B 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $1.72B 10-K · filed 2023-03-01 | |
| 2021-09-30 | $1.68B 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $1.63B 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $1.51B 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $1.50B 10-K · filed 2022-03-01 | $872.08M 10-K · filed 2021-03-04 |
| 2020-09-30 | $871.17M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $870.41M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $783.29M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $1.41B 8-K/A · filed 2021-04-22 | $782.97M 10-K · filed 2020-03-25 |
| 2019-09-30 | $782.55M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $782.31M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $781.79M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $741.25M 10-K · filed 2020-03-25 | |
| 2018-09-30 | $739.84M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $735.85M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $726.95M 10-Q · filed 2018-05-07 | |
| 2017-12-31 | $717.93M 10-K · filed 2019-03-13 | |
| 2017-09-30 | $709.35M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $700.64M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $691.23M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $680.76M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $669.62M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $651.33M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $625.20M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $606.55M 10-K · filed 2017-03-15 | |
| 2015-09-30 | $535.70M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $256.51M 10-Q · filed 2015-09-10 | |
| 2014-12-31 | $71.16M 10-K · filed 2016-03-30 | $71.16M 10-Q · filed 2015-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |